Polarean Imaging (POLX) Stock Overview
Operates as a drug-device manufacturer and service provider for noble gas hyperpolariser devices in Canada, the United Kingdom, and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
POLX Community Fair Values
See what others think this stock is worth. Follow their fair value or set your own to get alerts.
Polarean Imaging plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.0015 |
| 52 Week High | UK£0.017 |
| 52 Week Low | UK£0.0012 |
| Beta | -0.087 |
| 1 Month Change | -67.37% |
| 3 Month Change | -84.10% |
| 1 Year Change | -89.84% |
| 3 Year Change | -99.68% |
| 5 Year Change | -99.78% |
| Change since IPO | -99.03% |
Recent News & Updates
Recent updates
Shareholder Returns
| POLX | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | -11.4% | 1.1% | 0.5% |
| 1Y | -89.8% | 29.7% | 17.5% |
Return vs Industry: POLX underperformed the UK Medical Equipment industry which returned 29.7% over the past year.
Return vs Market: POLX underperformed the UK Market which returned 17.5% over the past year.
Price Volatility
| POLX volatility | |
|---|---|
| POLX Average Weekly Movement | 20.5% |
| Medical Equipment Industry Average Movement | 5.4% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.8% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: POLX's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: POLX's weekly volatility has increased from 13% to 21% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 26 | Chris Von Jako | polarean.com |
Polarean Imaging plc operates as a drug-device manufacturer and service provider for noble gas hyperpolariser devices in Canada, the United Kingdom, and the United States. The company engages in the research, development, and commercialization of novel imaging solutions with a non-invasive and radiation-free functional imaging platform. It also offers XENOVIEW, a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older; chest coil; Polarean 9820 Xenon hyperpolarizer that is designed to deliver up to 3 litres of hyperpolarized 129Xe per hour; and Polarean 2881 polarization measurement station, which provides a calibrated measurement of the polarization of hyperpolarized gas within the dose delivery inhalation bag.
Polarean Imaging plc Fundamentals Summary
| POLX fundamental statistics | |
|---|---|
| Market cap | UK£1.87m |
| Earnings (TTM) | -UK£7.30m |
| Revenue (TTM) | UK£1.95m |
Is POLX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| POLX income statement (TTM) | |
|---|---|
| Revenue | US$2.56m |
| Cost of Revenue | US$1.41m |
| Gross Profit | US$1.16m |
| Other Expenses | US$10.76m |
| Earnings | -US$9.60m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.008 |
| Gross Margin | 45.21% |
| Net Profit Margin | -374.12% |
| Debt/Equity Ratio | 0% |
How did POLX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/03 16:20 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Polarean Imaging plc is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colin Smith | Capital Access Group |
| Christian Glennie | Stifel, Equities Research |
| null null | Stifel, Equities Research |


